Sign up to save your data!
Some tips to help get started:
Processing...
There are 420 active trials for advanced/metastatic non-small cell lung cancer. Click on a trial to see more information.
420 trials meet filter criteria.
Sort by:
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors harboring documented KRAS mutations (excluding prior G12C inhibitor-treated G12C tumors), including NSCLC, CRC, pancreatic, and other KRAS-mutated cancers, who have progressed after standard therapies. Patients receive PF-07985045, a novel oral KRAS inhibitor, as monotherapy or in combination with chemotherapy, targeted agents, or immunotherapy, depending on cohort and tumor type.
ClinicalTrials.gov ID: NCT06704724
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors—including specific cohorts for EGFR-mutant or wild-type NSCLC, HNSCC, and metastatic CRC—to investigate AZD9592, a bispecific antibody-drug conjugate targeting EGFR and cMET, given alone or in combination with standard therapies such as osimertinib or 5-FU/bevacizumab/leucovorin. Key exclusions are active ILD/pneumonitis, untreated or unstable brain metastases, active infections, or significant cardiac disease.
ClinicalTrials.gov ID: NCT05647122
HealthScout AI summary: This trial enrolls adults with advanced, unresectable, or metastatic solid tumors harboring RAS or RAF pathway alterations (including mutations or fusions in KRAS, NRAS, BRAF, CRAF, or NF1) who have progressed after or are intolerant to standard therapies, to receive IK-595, an investigational oral dual MEK/RAF inhibitor designed to inactivate MEK and RAF signaling.
ClinicalTrials.gov ID: NCT06270082
HealthScout AI summary: This trial enrolls adults with advanced or metastatic solid tumors that are KRAS G12V-mutant and HLA-A*11:01 positive who have progressed after prior systemic therapy. Patients receive a single infusion of AFNT-211, an autologous T cell therapy engineered to express a TCR targeting HLA-A*11:01/KRAS G12V, following lymphodepleting chemotherapy.
ClinicalTrials.gov ID: NCT06105021
HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic NSCLC harboring EGFR (and in some cohorts, HER2) exon 20 insertion mutations who have received prior therapy, treating them with STX-721, an investigational oral irreversible tyrosine kinase inhibitor that selectively targets mutant EGFR and HER2.
ClinicalTrials.gov ID: NCT06043817
HealthScout AI summary: Eligible patients are adults with advanced or metastatic solid tumors harboring a KRASG12D mutation (including NSCLC, colorectal, and pancreatic cancers) who have progressed on standard therapy and have not previously received a direct KRAS inhibitor. The trial evaluates AZD0022, a selective oral KRAS G12D inhibitor, as monotherapy and in combination with cetuximab.
ClinicalTrials.gov ID: NCT06599502
HealthScout AI summary: Adults with advanced solid tumors and good performance status are eligible for this study of BMS-986507, a bispecific EGFR/HER3-targeting antibody-drug conjugate with a topoisomerase I inhibitor payload, in combination with either osimertinib or pembrolizumab. Key exclusions include untreated symptomatic CNS metastases, mixed SCLC/NSCLC, and severe infection or cardiac disease.
ClinicalTrials.gov ID: NCT06618287
HealthScout AI summary: Adult patients with advanced or metastatic solid tumors harboring a KRAS G12D mutation (including pancreatic, colorectal, or NSCLC), ECOG 0-1, and no prior KRAS G12D inhibitor exposure are eligible for treatment with INCB161734, a selective oral KRAS G12D inhibitor, given alone or in combination with standard therapies (e.g., gemcitabine/nab-paclitaxel, mFOLFIRINOX, cetuximab, or retifanlimab).
ClinicalTrials.gov ID: NCT06179160
HealthScout AI summary: This trial enrolls adults with advanced, unresectable or metastatic colorectal cancer, non-small cell lung cancer, non-nasopharyngeal head and neck squamous cell carcinoma, or pancreatic ductal adenocarcinoma who have progressed on or are intolerant to standard therapies. Patients will receive PF-08046052/SGN-EGFRd2, a bispecific antibody that targets EGFR and conditionally activates γ9δ2-T cells to promote anti-tumor immune responses.
ClinicalTrials.gov ID: NCT05983133
HealthScout AI summary: This trial enrolls adults with previously treated advanced MYC-driven or selected solid tumors—including NSCLC, SCLC, high-grade neuroendocrine cancers, L- or N-MYC amplified solid tumors, or diffuse large B-cell lymphoma—testing oral MRT-2359, a GSPT1-targeting molecular glue degrader, as monotherapy or in combination with fulvestrant (HR+/HER2- breast cancer) or enzalutamide (prostate cancer).
ClinicalTrials.gov ID: NCT05546268
